Abstract
High expression of SET and MYND domain-containing protein 2(SMYD2) has been reported as a poor prognostic factor for various types of cancer. However, there are little published data about clinical significance of SMYD2 in children with ALL. We used real-time polymerase chain reaction (PCR) to detect SMYD2 expression in the bone marrow (BM) samples from 134 newly diagnosed children with ALL. Our data showed that children with ALL demonstrated significantly higher SMYD2 expression than control group (p < .001). SMYD2 mRNA expression levels decreased significantly after complete remission. In addition, patients with higher SMYD2 expression had higher white blood cell count (p = .003) and higher percentage of high-risk groups (p = .005). Survival analyses showed that higher SMYD2 expression was associated with worse overall survival and event free survival (EFS) in children with B lineage ALL(B-ALL) and was an independent prognostic factor in multivariate analyses.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
